193 related articles for article (PubMed ID: 31462682)
1. Allogeneic hematopoietic stem cell transplantation with fludarabine, busulfan, and thiotepa conditioning is associated with favorable outcomes in myelofibrosis.
Shouval R; Vega Y; Fein JA; Danylesko I; Shem Tov N; Yerushalmi R; Sobas M; Czyż A; Nagler A; Shimoni A
Bone Marrow Transplant; 2020 Jan; 55(1):147-156. PubMed ID: 31462682
[TBL] [Abstract][Full Text] [Related]
2. Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis.
Murthy GSG; Kim S; Estrada-Merly N; Abid MB; Aljurf M; Assal A; Badar T; Badawy SM; Ballen K; Beitinjaneh A; Cerny J; Chhabra S; DeFilipp Z; Dholaria B; Perez MAD; Farhan S; Freytes CO; Gale RP; Ganguly S; Gupta V; Grunwald MR; Hamad N; Hildebrandt GC; Inamoto Y; Jain T; Jamy O; Juckett M; Kalaycio M; Krem MM; Lazarus HM; Litzow M; Munker R; Murthy HS; Nathan S; Nishihori T; Ortí G; Patel SS; Van der Poel M; Rizzieri DA; Savani BN; Seo S; Solh M; Verdonck LF; Wirk B; Yared JA; Nakamura R; Oran B; Scott B; Saber W
Haematologica; 2023 Jul; 108(7):1900-1908. PubMed ID: 36779595
[TBL] [Abstract][Full Text] [Related]
3. Busulfan- or Thiotepa-Based Conditioning in Myelofibrosis: A Phase II Multicenter Randomized Study from the GITMO Group.
Patriarca F; Masciulli A; Bacigalupo A; Bregante S; Pavoni C; Finazzi MC; Bosi A; Russo D; Narni F; Messina G; Alessandrino EP; Carella AM; Milone G; Bruno B; Mammoliti S; Bruno B; Fanin R; Bonifazi F; Rambaldi A;
Biol Blood Marrow Transplant; 2019 May; 25(5):932-940. PubMed ID: 30579966
[TBL] [Abstract][Full Text] [Related]
4. Thiotepa-busulfan-fludarabine as a conditioning regimen for patients with myelofibrosis undergoing allogeneic hematopoietic transplantation: a single center experience.
Memoli M; Paviglianiti A; Malard F; Battipaglia G; Brissot E; Médiavilla C; Bianchessi A; Banet A; Van de Wyngaert Z; Ledraa T; Belhocine R; Sestili S; Lapusan S; Hirsch P; Favale F; Boussaroque A; Bonnin A; Vekhoff A; Legrand O; Mohty M; Duléry R
Leuk Lymphoma; 2021 Feb; 62(2):419-427. PubMed ID: 33012207
[TBL] [Abstract][Full Text] [Related]
5. Thiotepa, busulfan and fludarabine compared to busulfan and cyclophosphamide as conditioning regimen for allogeneic stem cell transplant from matched siblings and unrelated donors for acute myeloid leukemia.
Saraceni F; Beohou E; Labopin M; Arcese W; Bonifazi F; Stepensky P; Aljurf M; Bruno B; Pioltelli P; Passweg J; Sociè G; Santarone S; Yakoub-Agha I; Lanza F; Savani BN; Mohty M; Nagler A;
Am J Hematol; 2018 Oct; 93(10):1211-1219. PubMed ID: 30033639
[TBL] [Abstract][Full Text] [Related]
6. Thiotepa-busulfan-fludarabine compared to busulfan-fludarabine for sibling and unrelated donor transplant in acute myeloid leukemia in first remission.
Saraceni F; Labopin M; Hamladji RM; Mufti G; Socié G; Shimoni A; Delage J; Deconinck E; Chevallier P; Blaise D; Sanz J; Huynh A; Forcade E; Savani BN; Mohty M; Nagler A;
Oncotarget; 2018 Jan; 9(3):3379-3393. PubMed ID: 29423053
[TBL] [Abstract][Full Text] [Related]
7. Comparable outcomes of haploidentical transplant with TBF conditioning versus matched unrelated donor with fludarabine/busulfan conditioning for acute myeloid leukemia.
Bazarbachi A; Labopin M; Blaise D; Forcade E; Socié G; Berceanu A; Angelucci E; Bulabois CE; Kröger N; Rambaldi A; Ceballos P; Mielke S; El Cheikh J; Yakoub-Agha I; Savani B; Spyridonidis A; Nagler A; Mohty M
Bone Marrow Transplant; 2021 Mar; 56(3):622-634. PubMed ID: 33020591
[TBL] [Abstract][Full Text] [Related]
8. Thiotepa-busulfan-fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the Chronic Malignancies Working Party of the EBMT.
Battipaglia G; Mauff K; Wendel L; Angelucci E; Mohty M; Arcese W; Santarone S; Rubio MT; Kroger N; Fox ML; Blaise D; Iori AP; Fanin R; Chalandon Y; Pioltelli P; Marotta G; Chiusolo P; Sever M; Solano C; Contentin N; de Wreede LC; Czerw T; Hernandez-Boluda JC; Hayden P; McLornan D; Yakoub-Agha I
Bone Marrow Transplant; 2021 Jul; 56(7):1593-1602. PubMed ID: 33526919
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic Hemopoietic Stem Cell Transplants in Patients with Acute Myeloid Leukemia (AML) Prepared with Busulfan and Fludarabine (BUFLU) or Thiotepa, Busulfan, and Fludarabine (TBF): A Retrospective Study.
Sora F; Grazia CD; Chiusolo P; Raiola AM; Bregante S; Mordini N; Olivieri A; Iori AP; Patriarca F; Grisariu S; Terruzzi E; Rambaldi A; Sica S; Bruno B; Angelucci E; Bacigalupo A
Biol Blood Marrow Transplant; 2020 Apr; 26(4):698-703. PubMed ID: 31875522
[TBL] [Abstract][Full Text] [Related]
10. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
Chen YB; Coughlin E; Kennedy KF; Alyea EP; Armand P; Attar EC; Ballen KK; Cutler C; Dey BR; Koreth J; McAfee SL; Spitzer TR; Antin JH; Soiffer RJ; Ho VT
Biol Blood Marrow Transplant; 2013 Jun; 19(6):981-7. PubMed ID: 23562738
[TBL] [Abstract][Full Text] [Related]
11. Haploidentical transplantation is associated with better overall survival when compared to single cord blood transplantation: an EBMT-Eurocord study of acute leukemia patients conditioned with thiotepa, busulfan, and fludarabine.
Giannotti F; Labopin M; Shouval R; Sanz J; Arcese W; Angelucci E; Sierra J; Santasusana JR; Santarone S; Benedetto B; Rambaldi A; Saccardi R; Blaise D; Carella MA; Rocha V; Baron F; Mohty M; Ruggeri A; Nagler A
J Hematol Oncol; 2018 Aug; 11(1):110. PubMed ID: 30165887
[TBL] [Abstract][Full Text] [Related]
12. Feasibility of thiotepa addition to the fludarabine-busulfan conditioning with tacrolimus/sirolimus as graft vs host disease prophylaxis.
Fox ML; García-Cadenas I; Pérez AM; Villacampa G; Piñana JL; Ortí G; Montoro J; Roldán E; Bosch Vilaseca A; Martino R; Salamero O; Saavedra S; Hernandez-Boluda JC; Esquirol A; Sierra J; Sanz J; Solano C; Bosch F; Barba P; Valcarcel D
Leuk Lymphoma; 2020 Aug; 61(8):1823-1832. PubMed ID: 32654570
[TBL] [Abstract][Full Text] [Related]
13. Effect of the Thiotepa Dose in the TBF Conditioning Regimen in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Complete Remission: A Report From the EBMT Acute Leukemia Working Party.
El-Cheikh J; Labopin M; Al-Chami F; Bazarbachi A; Angelucci E; Santarone S; Bonifazi F; Carella AM; Castagna L; Bruno B; Iori AP; La Nasa G; Savani B; Nagler A; Mohty M
Clin Lymphoma Myeloma Leuk; 2020 May; 20(5):296-304. PubMed ID: 32081702
[TBL] [Abstract][Full Text] [Related]
14. Outcome after Transplantation According to Reduced-Intensity Conditioning Regimen in Patients Undergoing Transplantation for Myelofibrosis.
Robin M; Porcher R; Wolschke C; Sicre de Fontbrune F; Alchalby H; Christopeit M; Cassinat B; Zabelina T; Peffault de Latour R; Ayuk F; Socié G; Kröger N
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1206-1211. PubMed ID: 26970380
[TBL] [Abstract][Full Text] [Related]
15. Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).
Saraceni F; Labopin M; Brecht A; Kröger N; Eder M; Tischer J; Labussière-Wallet H; Einsele H; Beelen D; Bunjes D; Niederwieser D; Bochtler T; Savani BN; Mohty M; Nagler A
J Hematol Oncol; 2019 Apr; 12(1):44. PubMed ID: 31023346
[TBL] [Abstract][Full Text] [Related]
16. Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
Lee KH; Lee JH; Lee JH; Kim DY; Park HS; Choi EJ; Ko SH; Seol M; Lee YS; Kang YA; Jeon M; Baek S; Kang YL; Kim SH; Yun SC; Kim H; Jo JC; Choi Y; Joo YD; Lim SN
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1555-1566. PubMed ID: 28552421
[TBL] [Abstract][Full Text] [Related]
17. Thiotepa, Busulfan, and Fludarabine Conditioning Regimen in T Cell-Replete HLA-Haploidentical Hematopoietic Stem Cell Transplantation.
Duléry R; Bastos J; Paviglianiti A; Malard F; Brissot E; Battipaglia G; Médiavilla C; Giannotti F; Banet A; de Wyngaert ZV; Ledraa T; Belhocine R; Sestili S; Adaeva R; Lapusan S; Isnard F; Legrand O; Vekhoff A; Rubio MT; Ruggeri A; Mohty M
Biol Blood Marrow Transplant; 2019 Jul; 25(7):1407-1415. PubMed ID: 30871978
[TBL] [Abstract][Full Text] [Related]
18. Thiotepa, Fludarabine, and Busulfan Conditioning Regimen before T Cell-Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia: A Bicentric Experience of 100 Patients.
Pagliardini T; Castagna L; Harbi S; Porta MD; Rey J; Fürst S; Bramanti S; Saillard C; Legrand F; Maisano V; Faucher C; Granata A; Hospital MA; Lining W; Weiller PJ; Calmels B; Charbonnier A; Lemarie C; Chabannon C; Vey N; Mokart D; Blaise D; Devillier R
Biol Blood Marrow Transplant; 2019 Sep; 25(9):1803-1809. PubMed ID: 31128325
[TBL] [Abstract][Full Text] [Related]
19. A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis.
Gooptu M; Kim HT; Ho VT; Alyea EP; Koreth J; Armand P; Ritz J; Nikiforow S; Glotzbecker BE; Nageshwar P; Soiffer RJ; Antin JH; Cutler CS
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1733-1740. PubMed ID: 29555313
[TBL] [Abstract][Full Text] [Related]
20. Myeloablative and Reduced-Intensity Conditioned Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis: A Retrospective Study by the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.
McLornan D; Szydlo R; Koster L; Chalandon Y; Robin M; Wolschke C; Beelen D; Socié G; Bornhäuser M; Angelucci E; Niederwieser D; Gerbitz A; Finke J; Vitek A; Itälä-Remes M; Radujkovic A; Kanz L; Potter V; Chevallier P; Stelljes M; Petersen E; Robinson S; Poiré X; Klyuchnikov E; Hernández-Boluda JC; Czerw T; Hayden P; Kröger N; Yakoub-Agha I
Biol Blood Marrow Transplant; 2019 Nov; 25(11):2167-2171. PubMed ID: 31284069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]